# US 2003/0215447 A1 · Inhibitory monoclonal antibody against blood clotting factor VII-activating protease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215447 A1
- Document ID: US20030215447A1
- Status: Published application
- Kind: A1
- Application number: 10/359,704
- Filed: 2003-02-07
- Published: 2003-11-20
- Earliest claimed: 2002-02-08
- Assignees: CSL Behring GmbH
- Inventors: Juergen Roemisch; Wiegand Lang; Annette Feussner; Gudrun Muth-Naumann; Hans-Arnold Stoehr; Christian Kannemaier; Klaus Preissner; Fumie Nakazawa
- Web page: https://patentgrep.com/patent/US20030215447A1

## CPC

- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- C07K 16/40: against enzymes
- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C12Q 1/37: involving peptidase or proteinase
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- A61K 2039/505: {comprising antibodies}
- G01N 2333/96447: Factor VII (3.4.21.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.

## Claims

### Claim 1

A monoclonal antibody which inhibits blood clotting factor VII-activating protease (FSAP) and its proenzyme.

### Claim 2 (depends on 1)

The monoclonal antibody as claimed in claim 1, which is produced by hybridoma cell line DSM ACC 2533.

### Claim 3 (depends on 1)

A hybridoma cell line, which produces an antibody as claimed in claim 1.

### Claim 4 (depends on 3)

The hybridoma cell line as claimed in claim 3, which is the hybridoma cell line deposited under accession number DSM ACC 2533.

### Claim 5 (depends on 1, 2)

The monoclonal antibody as claimed in claim 1, whose binding to FSAP is inhibited by the monoclonal antibody as claimed in claim 2.

### Claim 6 (depends on 2)

An epitope, which binds to the antibody as claimed in claim 2.

### Claim 7 (depends on 6)

A monoclonal antibody, which binds to the epitope as claimed in claim 6.

### Claim 8 (depends on 2)

A peptide, which competitively inhibits binding of the antibody as claimed in claim 2 to FSAP.

### Claim 9 (depends on 2)

A single-chain antibody, which has the binding specificity of the antibody as claimed in claim 2.

### Claim 10 (depends on 9)

The antibody as claimed in claim 9, which is bound to a carrier protein, preferably human serum albumin or human transferin.

### Claim 11 (depends on 2)

A humanized antibody, which has the binding specificity of the antibody as claimed in claim 2.

### Claim 12 (depends on 1, 2)

A stabilized, blood clotting factor VII-activating protease and its proenzyme, which is inhibited by the addition of a monoclonal antibody of either of claims 1 and 2.

### Claim 13 (depends on 1, 2)

A factor VII preparation, which contains a monoclonal antibody as claimed in either of claims 1 and 2, which antibody inhibits the factor VII-activating protease and its proenzyme.

### Claim 14 (depends on 1, 2)

A stabilized factor V, factor VIII or fibrinogen preparation, which is protected against proteolytic degradation by factor VII-activating protease due to inhibition of said protease by means of a monoclonal antibody of either of claims 1 and 2.

### Claim 15 (depends on 1, 2)

A pharmaceutical preparation for reducing the coagulability of blood, which contains a monoclonal antibody of either of claims 1 and 2.

### Claim 16 (depends on 1, 2)

A method for determining the activity of blood clotting factor VII-activating protease, wherein the amount of proteases contained in the sample to be studied is stabilized by the addition of a sufficient amount of a monoclonal antibody of either of claims 1 and 2 and the amidolytic activity remaining is measured only thereafter.

### Claim 17

A method for preparing FSAP or the FSAP proenzyme, which uses the monoclonal antibody as immunoadsorbent.

### Claim 18

A method for preparing FSAP or the FSAP proenzyme, wherein the monoclonal antibody is added to the starting material from which FSAP is obtained.

### Claim 19 (depends on 1, 2)

The use of the monoclonal antibody of claims 1 and 2 for preventing or reducing the risk of thrombosis and the coagulability of blood which has an increased FSAP content or FSAP proenzyme content.

### Claim 20 (depends on 1, 2)

The use of the monoclonal antibody of claims 1 and 2 for the treatment of disorders caused by fibrin-containing thrombi.
